Compare Stocks: CSCI, EVAX, QNCX, and CELU

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$0.98 -6.9%	$1.33	$0.56 ▼ $2.55	$31.73M	0.77	112,666 shs	145,347 shs
CSCI COSCIENS Biopharma	$2.72	$3.01	$2.50 ▼ $4.40	$8.64M	0.91	7,571 shs	N/A
EVAX Evaxion A/S	$3.76 +1.3%	$3.20	$2.72 ▼ $6.92	$33.92M	0.5	116,554 shs	161,649 shs
QNCX Quince Therapeutics	$31.73	$30.88	$15.10 ▼ $909.98	$32.27M	1.33	31,090 shs	N/A

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	0.00%	-21.78%	-25.93%	+30.36%	-51.36%
CSCI COSCIENS Biopharma	0.00%	0.00%	0.00%	0.00%	+4.21%
EVAX Evaxion A/S	0.00%	+32.86%	+15.34%	+28.33%	-30.88%
QNCX Quince Therapeutics	0.00%	0.00%	+5.77%	+77.76%	-91.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$0.98 -6.9%	$1.33	$0.56 ▼ $2.55	$31.73M	0.77	112,666 shs	145,347 shs
CSCI COSCIENS Biopharma	$2.72	$3.01	$2.50 ▼ $4.40	$8.64M	0.91	7,571 shs	N/A
EVAX Evaxion A/S	$3.76 +1.3%	$3.20	$2.72 ▼ $6.92	$33.92M	0.5	116,554 shs	161,649 shs
QNCX Quince Therapeutics	$31.73	$30.88	$15.10 ▼ $909.98	$32.27M	1.33	31,090 shs	N/A

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	0.00%	-21.78%	-25.93%	+30.36%	-51.36%
CSCI COSCIENS Biopharma	0.00%	0.00%	0.00%	0.00%	+4.21%
EVAX Evaxion A/S	0.00%	+32.86%	+15.34%	+28.33%	-30.88%
QNCX Quince Therapeutics	0.00%	0.00%	+5.77%	+77.76%	-91.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELU Celularity	1.00	Sell	N/A	N/A
CSCI COSCIENS Biopharma	0.00	N/A	N/A	N/A
EVAX Evaxion A/S	2.67	Moderate Buy	$11.00	192.55% Upside
QNCX Quince Therapeutics	2.64	Moderate Buy	$189.88	498.41% Upside

Current Analyst Ratings Breakdown

Latest CSCI, EVAX, QNCX, and CELU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	QNCX Quince Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$72.00
10/6/2026	EVAX Evaxion A/S	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/1/2026	QNCX Quince Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
9/29/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/29/2026	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/24/2026	QNCX Quince Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$70.00
9/24/2026	QNCX Quince Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$70.00
9/22/2026	QNCX Quince Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Market Perform ➝ Outperform
9/22/2026	QNCX Quince Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Market Perform ➝ Outperform	$77.00
8/27/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	QNCX Quince Therapeutics	Craig Hallum Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELU Celularity	$26.55M	1.19	N/A	N/A	($1.32) per share	-0.74
CSCI COSCIENS Biopharma	$9.44M	0.91	N/A	N/A	$3.49 per share	0.78
EVAX Evaxion A/S	$7.53M	4.50	N/A	N/A	$2.04 per share	1.84
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELU Celularity	-$91.72M	-$1.69	N/A	N/A	N/A	-246.65%	N/A	-48.20%	11/13/2026 (Estimated)
CSCI COSCIENS Biopharma	-$15.31M	-$6.01	N/A	N/A	N/A	-199.55%	-149.49%	-54.80%	N/A
EVAX Evaxion A/S	-$7.71M	-$1.21	N/A	N/A	N/A	N/A	-61.43%	-34.23%	11/5/2026 (Estimated)
QNCX Quince Therapeutics	-$83.98M	-$156.71	N/A	N/A	N/A	N/A	N/A	-133.84%	11/11/2026 (Estimated)

Latest CSCI, EVAX, QNCX, and CELU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/19/2026	Q3 2026	EVAX Evaxion A/S	-$0.01	N/A	N/A	N/A	$0.30 million	N/A
11/11/2026	Q3 2026	QNCX Quince Therapeutics	-$1.3850	N/A	N/A	N/A	N/A	N/A
10/20/2026	Q1 2026	CELU Celularity	N/A	$0.02	N/A	$0.02	N/A	$5.43 million
9/29/2026	Q1 2026	CELU Celularity	N/A	$0.02	N/A	$0.02	N/A	$3.85 million
8/14/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	-$12.31	+$15.71	-$12.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELU Celularity	N/A	N/A	N/A	N/A	N/A
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A
EVAX Evaxion A/S	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELU Celularity	N/A	0.11	0.10
CSCI COSCIENS Biopharma	N/A	2.98	2.65
EVAX Evaxion A/S	0.69	5.06	5.06
QNCX Quince Therapeutics	N/A	14.52	14.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELU Celularity	19.02%
CSCI COSCIENS Biopharma	0.73%
EVAX Evaxion A/S	11.04%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
CELU Celularity	17.30%
CSCI COSCIENS Biopharma	0.10%
EVAX Evaxion A/S	41.64%
QNCX Quince Therapeutics	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELU Celularity	115	32.45 million	26.84 million	Optionable
CSCI COSCIENS Biopharma	20	3.18 million	3.17 million	N/A
EVAX Evaxion A/S	46	9.02 million	5.27 million	No Data
QNCX Quince Therapeutics	38	1.02 million	960,000	No Data

CSCI, EVAX, QNCX, and CELU Headlines

Recent News About These Companies

Quince Therapeutics, Inc. (QNCX) - What Are Researchers Saying About This Stock?

October 19, 2026 | americanbankingnews.com

Quince Therapeutics Appoints Brigette Roberts, M.D. as CEO Amid Executive Changes and Rebranding

October 11, 2026 | kalkinemedia.comK

Quince Therapeutics Renames as IRulya Therapeutics, Advances Pulmonary Drug Development

October 9, 2026 | finance.yahoo.com

Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

October 9, 2026 | globenewswire.com

Quince Therapeutics stock wins approval for major share issuance

October 7, 2026 | ad-hoc-news.deA

Quince Shareholders Approve New Equity and Stock Plans

October 6, 2026 | tipranks.com

Leerink Partners Reaffirms Their Buy Rating on Quince Therapeutics (QNCX)

October 1, 2026 | theglobeandmail.com

Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript

September 28, 2026 | seekingalpha.com

Rodman & Renshaw initiates coverage of Quince Therapeutics with a buy

September 24, 2026 | msn.com

Quince Therapeutics stock falls 3.83 percent on Nasdaq

September 24, 2026 | ad-hoc-news.deA

Quince Therapeutics stock prepares for LAM-001 KOL event as shares trade below recent highs

September 19, 2026 | ad-hoc-news.deA

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on ...

September 17, 2026 | finance.yahoo.com

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

September 17, 2026 | globenewswire.com

Quince Therapeutics to Participate in September 2026 Investor Conferences

September 3, 2026 | quiverquant.comQ

Quince Therapeutics to Participate in September 2026 Investor Conferences

September 3, 2026 | globenewswire.com

Quince Therapeutics Announces Planned Presidential Leadership Transition

August 27, 2026 | tipranks.com

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

August 14, 2026 | globenewswire.com

Quince Therapeutics

July 6, 2026 | fool.com

Quince Therapeutics Stock Short Interest Report | NASDAQ:QNCX | Benzinga

July 2, 2026 | benzinga.com

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

June 30, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSCI, EVAX, QNCX, and CELU Company Descriptions

Celularity NASDAQ:CELU

$0.98 -0.07 (-6.89%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$0.97 -0.01 (-0.79%)

As of 10/23/2026 07:30 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

COSCIENS Biopharma NASDAQ:CSCI

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Evaxion A/S NASDAQ:EVAX

$3.76 +0.05 (+1.35%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$3.86 +0.10 (+2.63%)

As of 10/23/2026 07:50 PM Eastern

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Quince Therapeutics NASDAQ:QNCX

$31.73 0.00 (0.00%)

As of 10/13/2026

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CSCI, EVAX, QNCX, and CELU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CSCI, EVAX, QNCX, and CELU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CSCI, EVAX, QNCX, and CELU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSCI, EVAX, QNCX, and CELU Company Descriptions

Celularity NASDAQ:CELU

COSCIENS Biopharma NASDAQ:CSCI

Evaxion A/S NASDAQ:EVAX

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CSCI, EVAX, QNCX, and CELU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CSCI, EVAX, QNCX, and CELU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CSCI, EVAX, QNCX, and CELU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSCI, EVAX, QNCX, and CELU Company Descriptions

Celularity NASDAQ:CELU

COSCIENS Biopharma NASDAQ:CSCI

Evaxion A/S NASDAQ:EVAX

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools